Ireland - English - HPRA (Health Products Regulatory Authority)

essential pharmaceuticals limited - vitamin a palmitate; ergocalciferol; choline chloride; cyanocobalamin - liquid - 0 percent volume/volume - multivitamins, plain

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - liquid glucose, quantity: 600 mg/ml; guaifenesin, quantity: 20 mg/ml; treacle, quantity: 270 mg/ml - oral liquid - excipient ingredients: caramel; chloroform; sodium metabisulfite; capsicum frutescens; purified water; camphor; xanthan gum; sodium benzoate; sodium cyclamate; glacial acetic acid; macrogol 300; menthol; acesulfame potassium; flavour - expectorant and demulcent.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - liquid paraffin, quantity: 1 ml/ml - liquid, multipurpose - excipient ingredients: - decrease/reduce/relieve constipation ; aperient/laxative ; helps reduce occurrence of constipation ; decrease/reduce/relieve skin dryness

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

vital supplies limited, tanzania - liquid paraffin - solution - 100%v/v

Australia - English - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 4000 mg - liquid, multipurpose - excipient ingredients: monobasic sodium phosphate monohydrate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1- antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 500 mg - liquid, multipurpose - excipient ingredients: monobasic sodium phosphate monohydrate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1- antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

wilchem - ammonium sulfate(425g/l) - liquid concentrate - spray adjuvant - herbicide additive | activator | penetrant | post emergent herbicide | spreading adjuvant | surfactant | wetting agent - tank mixing | additive | agricultural chemical | herbicide | minimise antagonism | spray tank

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

kck pharmaceutical industries sdn. bhd. - liquid paraffin -

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - codeine phosphate hemihydrate, quantity: 5 mg/ml - oral liquid - excipient ingredients: glycerol; propylene glycol; purified water; sucrose; methyl hydroxybenzoate - relief of unproductive, dry and intractable coughs associated with colds and flu relief of unproductive, dry and intractable coughs associated with colds and flu.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - clonazepam, quantity: 2.5 mg/ml - oral liquid, solution - excipient ingredients: saccharin sodium; propylene glycol; brilliant blue fcf; glacial acetic acid; flavour - tablets. most types of epilepsy in infants and children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalised epilepsy, or to secondary generalisation of partial epilepsy. in adults all varieties of generalised epilepsy, (including myoclonic, akinetic, tonic and tonic-clonic seizures), and in partial epilepsy (including psychomotor seizures). injection. intravenous use for status epilepticus only. note. efficacy by the intramuscular route has not need demonstrated.